摘要
目的探讨血浆D-二聚体、纤维蛋白原两项指标检测用于临床鉴别诊断肺癌病理类型及预后的相关性。方法选择2020年5月至2022年9月常熟市第一人民医院收治的肺癌患者202例作为观察目标,均对其血浆D-二聚体、纤维蛋白原指标进行检测,以病理诊断结果为金标准,比较不同类型肺癌患者两项指标结果差异,同时结合患者预后分析不同肿瘤分期患者两项指标的组间差异。结果通过病理诊断,202例肺癌患者中,72例确诊为鳞癌、75例确诊为腺癌、55例确诊为小细胞癌。肺鳞癌患者D-二聚体及纤维蛋白原测定值均明显小于肺腺癌及小细胞肺癌患者,差异有统计学意义(P<0.05)。归纳患者预后分期,80例患者为Ⅰ/Ⅱ期、55例患者为Ⅲ期、67例患者为Ⅳ期。Ⅳ期肺癌患者D-二聚体及纤维蛋白原测定值明显大于其他分期肺癌患者,差异有统计学意义(P<0.05)。结论临床测定血浆D-二聚体、纤维蛋白原两项指标可作为肺癌病理类型鉴别的依据,同时该指标与患者预后存在相关性,值得运用推广。
Objective To investigate the correlation of plasma D-dimer and fibrinogen levels with clinicopathological types and prognosis of lung cancer.Methods A total of 202 lung cancer patients admitted to Changshu No.1 People’s Hospital from May 2020 to September 2022 were selected as observation subjects.These patients were subjected to plasma D-dimer and fibrinogen levels testing for comparison among patients with different pathological types of lung cancer using the pathological diagnosis results as the gold standard,and the differences in the two indicators among patients with different tumor stages were also analyzed in the context of patient prognosis.Results Pathological diagnosis suggested 72 patients with squamous cell carcinoma,75 with adenocarcinoma,and 55 with small cell carcinoma among 202 lung cancer patients.The levels of D-dimer and fibrinogen in patients with squamous cell lung carcinoma were significantly lower than those in patients with lung adenocarcinoma and small cell carcinoma of lung,with statistically significant differences(P<0.05).Taking into account the prognosis,80 patients were classified as stagesⅠ/Ⅱ,55 patients as stageⅢ,and 67 patients as stageⅣ.The levels of D-dimer and fibrinogen in patients with stageⅣlung cancer were significantly greater than those in patients with other lower stages of lung cancer,with statistically significant differences(P<0.05).Conclusion The clinical testing results of plasma D-dimer and fibrinogen can be used as a basis for differentiating the pathological types of lung cancer and correlate with the prognosis of patients,which is worthy of application and promotion.
作者
夏迪
XIA Di(Department of Respiratory and Critical Care Medicine,Affiliated Changshu Hospital of Soochow University,Changshu No.1 People’s Hospital,Jiangsu,Changshu 215500,China)
出处
《中国医药科学》
2023年第13期188-190,198,共4页
China Medicine And Pharmacy
